Vivo Capital, OrbiMed Lead $80M Series B Round In Biopharmaceutical Start-Up Terns Pharmaceuticals

Login to View

Terns Pharmaceuticals, a US and Shanghai-based biopharmaceutical start-up, has raised US$80 million in series B round of financing led by Vivo Capital and OrbiMed.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in